{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:27:31Z","timestamp":1790620051960,"version":"4.1.0"},"reference-count":35,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T00:00:00Z","timestamp":1652486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health-CCM Project Fasc","award":["1S04"],"award-info":[{"award-number":["1S04"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Here, we evaluated over time in different cohorts of children vaccinated against serogroup C Neisseria meningitidis, the presence of antibodies with neutralizing activity. A total of 348 sera samples of enrolled children by year since vaccination (&lt;1 year- up to 5 years), starting from February 2016 to December 2017, were collected in three collaborating centers. Meningococcal serogroup C (MenC) antibody titers were measured with a serum bactericidal antibody (SBA) assay using rabbit complement (rSBA) following standard operating procedures. The cut-off of rSBA titer \u2265 8 is considered the correlate of protection. We observed a significantly declining of bactericidal rSBA titers by 23% every year, for every 1-year from vaccination (Adjusted PR = 0.77, 95% CI: 0.71\u20130.84). The proportions of children with bactericidal antibodies, immunized with the meningococcal serogroup C conjugate (MCC) vaccine, declined from 67.7% (95% CI: 48.6\u201383.3%) one year after vaccination, to 36.7% (95% CI: 19.9\u201356.1%) five years after vaccination (chi-square for linear trend, p &lt; 0.001). Children vaccinated with the tetravalent meningococcal serogroup ACWY vaccine resulted in a high proportion of bactericidal rSBA MenC titer \u2265 1:8 (90.6%, 95% CI: 79.3\u201396.9%) after a mean time of seven months. Overall, the results provide some evidences on the evaluation of meningococcal serogroup C bactericidal antibodies after primary vaccination.<\/jats:p>","DOI":"10.3390\/vaccines10050778","type":"journal-article","created":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T09:48:22Z","timestamp":1652608102000},"page":"778","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of Meningococcal Serogroup C Bactericidal Antibodies after Primary Vaccination: A Multicentre Study, Italy"],"prefix":"10.3390","volume":"10","author":[{"given":"Arianna","family":"Neri","sequence":"first","affiliation":[{"name":"Department Infectious Diseases, Istituto Superiore di Sanit\u00e0, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Fabiani","sequence":"additional","affiliation":[{"name":"Department Infectious Diseases, Istituto Superiore di Sanit\u00e0, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0220-8211","authenticated-orcid":false,"given":"Anna","family":"Barbui","sequence":"additional","affiliation":[{"name":"Microbiology and Virology Laboratory, Citt\u00e0 della Salute e della Scienza Hospital, 10126 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7470-1713","authenticated-orcid":false,"given":"Caterina","family":"Vocale","sequence":"additional","affiliation":[{"name":"Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Miglietta","sequence":"additional","affiliation":[{"name":"Central Tuscany Health Authority, 50142 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Fazio","sequence":"additional","affiliation":[{"name":"Department Infectious Diseases, Istituto Superiore di Sanit\u00e0, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Carannante","sequence":"additional","affiliation":[{"name":"Department Infectious Diseases, Istituto Superiore di Sanit\u00e0, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7220-1862","authenticated-orcid":false,"given":"Annapina","family":"Palmieri","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Endocrine-Metabolic Diseases and Aging, Istituto Superiore di Sanit\u00e0, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Vacca","sequence":"additional","affiliation":[{"name":"Department Infectious Diseases, Istituto Superiore di Sanit\u00e0, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9063-3973","authenticated-orcid":false,"given":"Luigina","family":"Ambrosio","sequence":"additional","affiliation":[{"name":"Department Infectious Diseases, Istituto Superiore di Sanit\u00e0, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Stefanelli","sequence":"additional","affiliation":[{"name":"Department Infectious Diseases, Istituto Superiore di Sanit\u00e0, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Stefanelli, P., Fazio, C., Sofia, T., Neri, A., and Mastrantonio, P. (2009). Serogroup C meningococci in Italy in the era of conjugate menC vaccination. BMC Infect. Dis., 9.","DOI":"10.1186\/1471-2334-9-135"},{"key":"ref_2","unstructured":"Istituto Superiore Di Sanit\u00e0 (2022, April 20). ISS Surveillance Data on Invasive Bacterial Diseases, Consolidated Report 2019. Available online: https:\/\/www.iss.it\/-\/rapporto-consolidato-mib-2019."},{"key":"ref_3","unstructured":"(2022, April 20). PNPV 2005\u20132007, Available online: http:\/\/www.salute.gov.it\/imgs\/C_17_pubblicazioni_543_allegato.pdf."},{"key":"ref_4","unstructured":"(2022, April 20). PNPV 2012\u20132014, Available online: http:\/\/www.salute.gov.it\/imgs\/C_17_pubblicazioni_1721_allegato.pdf."},{"key":"ref_5","unstructured":"(2022, April 20). PNPV 2017-2019, Available online: http:\/\/www.salute.gov.it\/imgs\/C_17_pubblicazioni_2571_allegato.pdf."},{"key":"ref_6","unstructured":"Ministry of Health (2022, April 20). Vaccine Coverage, Available online: https:\/\/www.salute.gov.it\/portale\/documentazione\/p6_2_8_3_1.jsp?lingua=italiano&id=20."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Sabbatucci, M., Odone, A., Signorelli, C., Siddu, A., Maraglino, F., and Rezza, G. (2022). Improved Temporal Trends of Vaccination Coverage Rates in Childhood after the Mandatory Vaccination Act, Italy 2014\u20132019. Vaccines, 10.","DOI":"10.3390\/jcm10122540"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/527401","article-title":"Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity","volume":"197","author":"Maiden","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1574-6976.2006.00060.x","article-title":"A surveillance network for meningococcal disease in Europe","volume":"31","author":"Trotter","year":"2007","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/INF.0b013e31819040e7","article-title":"The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada, Canadian Immunization Monitoring Program, Active (IMPACT)","volume":"28","author":"Bettinger","year":"2009","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_11","first-page":"108","article-title":"Impact of meningococcal C conjugate vaccine use in Australia (Editorial)","volume":"186","author":"Booy","year":"2007","journal-title":"MJA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1016\/j.vaccine.2013.07.083","article-title":"Effectiveness of meningococcal serogroup C vaccine programmes","volume":"31","author":"Borrow","year":"2013","journal-title":"Vaccine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2249.2000.01109.x","article-title":"Conjugate vaccines","volume":"119","author":"Goldblatt","year":"2000","journal-title":"Clin. Exp. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1086\/317646","article-title":"Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers","volume":"183","author":"Richmond","year":"2001","journal-title":"J. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.vaccine.2005.07.060","article-title":"Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP\/Hib vaccine","volume":"24","author":"Southern","year":"2006","journal-title":"Vaccine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/01.inf.0000151029.58752.27","article-title":"Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine","volume":"24","author":"Snape","year":"2005","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e20162193","DOI":"10.1542\/peds.2016-2193","article-title":"Active Bacterial Core Surveillance (ABCs) Team and MeningNet Surveillance Partners. Effectiveness and Duration of Protection of One Dose of a Meningococcal Conjugate Vaccine","volume":"139","author":"Cohn","year":"2017","journal-title":"Pediatrics"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1080\/21645515.2015.1136040","article-title":"Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants","volume":"12","author":"Baxter","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1080\/21645515.2020.1733869","article-title":"Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: A Phase II randomized study","volume":"16","author":"Vesikari","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/cdli.4.2.156-167.1997","article-title":"Standardization and a multi-laboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection--serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-7954-11-17","article-title":"Global epidemiology of invasive meningococcal disease","volume":"11","author":"Jafri","year":"2013","journal-title":"Popul. Health Metr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1586\/erv.09.48","article-title":"Meningococcal vaccines and herd immunity: Lessons learned from serogroup C conjugate vaccination programs","volume":"8","author":"Trotter","year":"2009","journal-title":"Expert Rev. Vaccines"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"B112","DOI":"10.1016\/j.vaccine.2009.04.065","article-title":"Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease","volume":"27","author":"Frasch","year":"2009","journal-title":"Vaccine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1128\/IAI.01945-06","article-title":"The Neisseria meningitidis capsule is important for intracellular survival in human cells","volume":"75","author":"Spinosa","year":"2007","journal-title":"Infect. Immun."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4161\/viru.26515","article-title":"Meningococcal disease and the complement system","volume":"5","author":"Lewis","year":"2014","journal-title":"Virulence"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(03)00740-0","article-title":"Host genetic determinants of Neisseria meningitidis infections","volume":"3","author":"Emonts","year":"2003","journal-title":"Lancet Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40121-019-0254-1","article-title":"Epidemiologic Trends, Global Shifts in Meningococcal Vaccination Guidelines, and Data Supporting the Use of MenACWY-TT Vaccine: A Review","volume":"8","author":"Presa","year":"2019","journal-title":"Infect. Dis. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1016\/j.vaccine.2009.05.047","article-title":"Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine","volume":"27","author":"Sakou","year":"2009","journal-title":"Vaccine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1086\/344324","article-title":"Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom","volume":"186","author":"Borrow","year":"2002","journal-title":"J. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1097\/INF.0000000000000438","article-title":"Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents","volume":"33","author":"Baxter","year":"2014","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/j.vaccine.2015.02.049","article-title":"Antibody persistence 5 years after vaccination at 2 to 10 years of age with Quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination","volume":"33","author":"Block","year":"2015","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/21645515.2015.1058457","article-title":"Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine","volume":"12","author":"Vesikari","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00431-012-1924-0","article-title":"Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2\u201310-year-old children: Results of an open, randomised, controlled study","volume":"172","author":"Knuf","year":"2013","journal-title":"Eur. J. Pediatr."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1128\/CVI.00384-09","article-title":"Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine","volume":"17","author":"Borrow","year":"2010","journal-title":"Clin. Vaccine Immunol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/5\/778\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:10:43Z","timestamp":1760137843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/5\/778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,14]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["vaccines10050778"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10050778","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,14]]}}}